Cue Biopharma Inc (NAS:CUE)
$ 1.56 -0.09 (-5.45%) Market Cap: 75.88 Mil Enterprise Value: 51.74 Mil PE Ratio: 0 PB Ratio: 2.52 GF Score: 52/100

Q2 2020 Cue Biopharma Inc Earnings Call Transcript

Aug 31, 2020 / 08:30PM GMT
Release Date Price: $17.87 (+0.79%)
Operator

Thank you for standing by. This is the conference operator. Welcome to the Cue Biopharma Second Quarter 2020 Earnings Call. (Operator Instructions)

The conference is being recorded. (Operator Instructions)

I would now like to turn the conference over to George Zavoico, Vice President, Investor Relations and Corporate Development. Please go ahead.

Unidentified Company Representative

Thank you, and good afternoon, everyone. Thank you for joining us on today's investor and Analyst update call. Joining me on the call today are Dan Passeri, Cue Biopharma's CEO. Dr. Anish Suri, President and Chief Scientific Officer; Dr. Ken Pienta, acting Chief Medical Officer; and Kerri-Ann Millar, Chief Financial Officer.

Before we begin, I would like to remind you that during today's call, the company will be making forward-looking statements. Various remarks that the company makes during this call about the company's future expectations, plans and prospects constitute forward-looking statements for purposes of the private Securities Litigation Reform Act of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot